Go to Page # Page of 51

Stroke Prevention - The Intersection of Cardiology & Neurology

 Michael R.K. Jacoby MD
Description: Dyslipidemia: - Statin therapy if significant 10-year stroke risk. Nonstatins if statins not tolerated but no established efficacy. Other Cardiac: - Mitral stenosis with embolic event– Anticoagulation. Mitral stenosis with LA thrombus – Anticoagulation. Aortic mechanical valve – Warfarin (INR 2-3) + aspirin 81 mg, With risk factors (INR 2.5-3.5) +ASA 81 mg. Other mechanical valves (INR 2.5-3.5)+ASA 81 mg.
Views: 711
Domain: Medical
Category: Therapy
Contributing Organization: Iowa Heart Foundation
 ‐ More of their Presentations
Stroke Prevention 2016

Intersection of Cardiology & Neurology
Summary of Recommendations
Michael R.K. Jacoby, MD, FAHA
Medical Director, Mercy Stroke Center

Stroke Disclosures
•  Speaker for Boehringer-Ingelheim

Stroke 2016
Summary of Recommendations
•  American Stroke Association
•  American Heart Association
•  American Academy of Neurology
... See more

Recent Presentations

Oncolytic Immunotherapeutics Leadership

The presentation and the accompanying oral commentary contain forward-looking statements within the meaning of the relevant securities laws of the Republic of Korea and the United

SillaJen Inc
18 March, 2018

Basket and Umbrella Trial Designs in Oncology

Historically, phase I conducted with mixture of solid tumors, then phase II and III oncology trials were histopathologic focused (e.g. lung cancer study, breast cancer study, etc.)

Eric Polley
17 March, 2018

Multidisciplinary Approachs in Cancer

The oncology framework is increasingly complex, entailing multiple interactions of all stakeholders involved: patients, European and national policy makers, European and internatio

16 March, 2018